The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | Richter’s syndrome and its impact on CLL patients
Matthew Davids, MD, MMSc, from the Dana-Farber Cancer Institute, Boston, MA, discusses the poor outcomes of chronic lymphocytic leukemia (CLL) patients who develop Richter’s syndrome upon receiving treatment and describes a multi-institutional study evaluating a cohort of these patients and their remission rates, which were generally low, thereby highlighting a clear unmet medical need for these patients. There does appear to be some promise though, as highlighted by Prof. Davids, since a few patients did achieve complete remission. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
